Opportunities and challenges of patient-derived models in cancer research: patient-derived xenografts, patient-derived organoid and patient-derived cells

• Published in: World journal of surgical oncology Vol. 20; no. 1; pp. 37 - 9
• Main Authors: Hou, Xiaoying, Du, Cong, Lu, Ligong, Yuan, Shengtao, Zhan, Meixiao, You, Pengtao, Du, Hongzhi
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 17.02.2022; BioMed Central; BMC
• Subjects: 20th century; Animal models; Animals; Antineoplastic Agents - therapeutic use; Antitumor agents; Cancer; Cancer research; Care and treatment; Cell culture; Clinical medicine; Clinical trials; Disease Models, Animal; Drug development; Heterografts; Human body; Humans; Laboratories; Medical research; NCI-60; Neoplasms - drug therapy; Oncology, Experimental; Organoids; Patient-derived cell (PDC); Patient-derived model; Patient-derived organoid (PDO); Patient-derived xenograft (PDX); Patients; Pharmaceutical industry; Pharmacodynamics; Review; Success; Systems analysis; Xenograft Model Antitumor Assays; Xenografts; Xenotransplantation; China; Patient-derived cell (PDC); Patient-derived model; Patient-derived organoid (PDO); Patient-derived xenograft (PDX); NCI-60

As reported, preclinical animal models differ greatly from the human body. The evaluation model may be the colossal obstacle for scientific research and anticancer drug development. Therefore, it is essential to propose efficient evaluation systems similar to clinical practice for cancer research. W...